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An important factor determining the pathological consequences in vivo of
infectionwith murine leukemia viruses(MuLW is that segment ofchromosome
17 bearing the major histocompatibility complex ofmice, the histocompatibility-
2 (H2) system (1). The particular event of the leukemogenic process directly
influenced byH-2 type has yet to be identified, but sinceH2 has no demonstra-
ble effect on the susceptibility of cultured cells to infection by MuLV (2), this
event is not at the level of cellular susceptibility to virus per se .
We have recently examined tumors induced by the Friend erythroleukemia
virus complex (FV) in mice oftwo highly congenic strains differing with respect
to the H2 chromosomal region : BALB/c (H2d) and BALB/cH-2° (BALB.B).
These tumors were maintained by subcutaneous transplantation in syngeneic
hosts for several transfers and then adapted to growth in culture. We have
alreadyreportedonsome aspects of ourfindings with thesetumor cell lines, i.e .,
production of infectious FV and growth characteristics in syngeneic hosts .
Essentially, cells of the BALB/c tumor line, which readily produce tumors in
vivo, ceased producing detectable levels of virus after arelatively briefresidence
in culture . Onthe other hand, BALB.B tumor cells, which grow poorly in vivo,
have continued to yield complete, infectious FV throughout their 2-yr culture
history (3) .
Each of the contrasting findings with these two cell lines, the marked differ-
ence in growth in vivo and the production or nonproduction of infectious virus,
mightbe areflection of important antigenic differencesbetweenthese lines. For
this reason, we have examined the expression on these cells of virus-associated
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antigens. Ourfindings indicate that both cell lines bear tumor-associated trans-
plantation antigens capable of inducing transplantation immunity in syngeneic
hosts. There was, however, no simple relationship between these transplanta-
tion antigens and a particular viral antigen.
Materials and Methods
Mice.
￿
All mice were from our own colony of highly inbred mouse strains. The congenic mouse
strain, BALB .B, was derived from the (BALB/c x C57BL/10)F, cross. 13 consecutive generations of
backcrosses to BALB/c were performed, with selection in each generation for theH-2° haplotype of
the C57BL/10 parent. The strain was then inbred. Animals were usually 6-10-wk old atthe time of
inoculation.
Viruses.
￿
The variant N-NB-tropic strain of FV was used throughout these experiments (4).
This strain is equally infectious in both DBA/2 (Fv-1") and BALB/c (Fv-1") mice. Virus prepara-
tions were made from the greatly enlarged spleens of infected BALB/c mice. 2 wk after infection
the spleens were homogenized in nine times their weight ofcold phosphate-buffered saline (PBS),
the homogenate centrifuged slowly at 4°C to remove large particulate matter, and the supernate
recentrifuged for 4 min at 7,000 g. The resulting supernate served as the basic virus preparation
and was stored in small ampules at -70°C.
N--+NB-tropic Friend lymphatic leukemia virus (LLV-F) was derived from N-tropic FV by
passage into newborn C57BL (Fv-1°) mice followed by blind passage in weanling Ha/ICR swiss
mice (5). Conversion to NB-tropism was afforded by five serial passages in BALB/c mice. Stocks of
LLV-F were prepared as 20% perfusates of leukemic BALB/c spleens and were free of detectable
spleen focus-forming activity.
Enlarged spleens were pooled, perfused with McCoy's medium containing 3% fetal calf serum,
the perfusate clarified at 2400g for 10 min and stored at -196°C. Stocks ofLLV-F were titrated for
their helper activity for the defective spleen focus-forming component (SFFV) of FV by the method
of Steeves et al. (6) and showed 8 x 10' helper U per ml.
Tumors.
￿
Tumors of FV-transformed cells were established by the method of Buffet and Furth
(7) and Friend and Haddad (8). This procedure involved subcutaneous transplantation to syngeneic
hosts of washed fragments of the greatly enlarged spleens of mice infected 25-28 days earlier with
N-->NB-tropic FV. Tumors of both BALB/c and BALB.B mice were established and passed
serially in their respective syngeneic hosts. Tumors ofBALB/c origin are referred to as HFL/d-ac;
"d" refers to the H-2 type of the mouse from which this tumor was derived; "ac" refers to
subcutaneous passage. Similarly, tumors of BALB.B origin are called HFL/b-sc.
Tissue Culture.
￿
All cell lines grown in culture were established from their respective subcuta-
neous solid tumors. These lines consisted of nonadherent cells maintained in suspension culture
by planting 5-ml samples containing 5 x 10° cells/ml in T-30 flasks and subculturing approxi-
mately 5 days later when the cell concentration reached 5 x 1(18 cells/ml. The growth medium used
throughout was Eagle's minimum essential medium with Earle's base (MEM-Earle's) plus 0.58
mg/ml L-glutamine, 100 U/ml penicillin and 100 mcg/ml streptomycin supplemented with 20% fetal
calf serum. Cell lines originating from BALB/c tumors are called HFL/d-tc, those of BALB.B
origin, HFL/b-tc. These cell lines have been in continuous serial culture for at least 2 yr.
Virus Neutralization Assay.
￿
Immune sera were tested for FV-neutralizing activity by the
method of Steeves and Axelrad (9) . Diluted sera and virus were combined at time zero and
incubated at 37°C. Samples were removed from the reaction tubes at 10- or 15-min intervals for up
to 40 min, appropriately diluted in ice-cold PBS, and immediately assayed in groups of seven
BALB/c mice for residual virus capable ofproducing spleen foci. Antisera potencies were expressed
in terms of the inactivation constant, K, determined from the equation K = (Dlt) Loge (V,/V,),
whereD = dilution ofantiserum, Vo = virus titer at time zero, and t = virus titer at time t. Neutrali-
zation of LLV by immune sera was tested by the method of Steeves et al. (6).
Antisera .
￿
Antiserum specific for the alloantigen H-2K.31 was prepared by hyperimmunization
of A/J mice with cells of the methylcholanthrene-induced BALB/c sarcoma, Meth A. Anti-FV
serum, containing both cytotoxic (anti-FMR) and virus-neutralizing (anti-virus envelope antigen
[VEAL) activity, was prepared by hyperimmunization of BALB/c or BALB.B mice with N--)-NB-
tropic FV grown in syngeneic mice. Anti-HFL/d-tc was prepared by hyperimmunization of BALB/cHERBERT A. FREEDMAN, FRANK LILLY, AND RICHARD A. STEEVES 1367
mice with HFL/d-tc cells after regression of HFL/d-tc-produced subcutaneous tumors . Assays of
these sera for cytotoxic activity were performed in the presence of guinea pig complement using
appropriate s'Cr-labeled target cells (10, 11) .
Absorption of Anti-FV.
￿
For the quantitative absorption of anti-FV serum, cells were har-
vested, washed fivetimes in medium 199, andresuspended to aconvenient volume . Thenumber of
viable cells, determined by exclusion of trypan blue (0.4% in normal saline), was >90% . Serial
twofold dilutions of viable cells were mixedwith antiserumappropriately diluted with medium 199
and incubated at 37°C with shaking for 1 h, followed by incubation at 4°C with shaking for an
additional hour . The suspensions were then centrifuged at 300g for 15 min and the resultant
supernate assayed in thepresence ofguinea pigcomplement for residual cytotoxic activity toward
s'Cr-labeled BALB/c spleen cells infected 7-11 days earlier with N-NB tropic FV .
Results
InductionofTransplantationImmunity .
￿
Cultured cells ofboth theHFL/d-tc
and HFL/b-tc lines induced tumors when inoculated into their respective synge-
neic hosts. These tumors often grew only transiently and then regressed. In both
cases regressor mice showed immunity to the growth ofa second inoculation of
the same cells. Thus thesecells appeared to possess tumor-associated transplan-
tation antigens .
The growth and regression of HFL/b-tc cells in BALB.B mice was noted in a
previous article (3) . Inoculation of fewer than 10 8 viable cells subcutaneously
never resulted in tumor growth in normal recipients . BALB .B mice injected
subcutaneously with 108 HFL/b-tc cells did show tumor growth, followed by
regression . 6 mo later four of these mice and four normal controls received
subcutaneous solid tumor implantations (strips about 2-cm long and 1-mm in
diameter) of the HFL/b-sc tumor, from which the HFL/b-tc cell line originated .
Tumor growth occurred only in the four normal control mice, whereas the
animals previously exposed to HFL/b-tc cells showed no detectable tumor devel-
opment .
HFL/d-tc cells, tested through passage 100 in culture, also showed a marked
capacity for inducing tumorimmunity insyngeneicBALB/c hosts, although to a
considerably lesser degree than that observed in BALB.B mice inoculated with
HFL/b-tc cells. Subcutaneous inoculation of 106 HFL/d-tc cells in normal synge-
neic hosts resulted in the development of a palpable tumor, 0.5-1 .0 cm in
diameter, within 7-10 days . Table I shows that more than half of these mice
appeared tumor-free 18-21 days later .
All regressor mice within each group noted in Table I were rechallenged
TABLE I
Regression ofTumors Resulting from Subcutaneous Inoculation
of106 HFLld-tc Cells in BALBlc mice
HFL/d-tcpassagenumber in cul-
ture
Number of tumors regress-
ing/number of tumors
9 4/6
13 9/9
21 5/7
22 6/7
24 7/91368
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subcutaneously, at least 16 days after tumor regression, with 106 viable HFL/d-
tc cells . None of these mice showed detectable tumor development, although
0.5-1-cm tumors developed at least transiently in all normal control mice
similarly inoculated . Thereafter it was possible to hyperimmunize these regres-
sor mice with progressively increasing doses of HFL/d-tc cells (see below) .
Since both HFL/b and HFL/d cells originated from tumors induced in vivo
with FV, they might both be expected to show FV-associated cell surface
specificities which could function as transplantation antigens . This is particu-
larly likely in the case of HFL/b-tc cells, since these cells produce complete,
infectious FV and release it into the culture medium . HFL/d-tc cells, which
produce no detectable levels of infectious FV, nevertheless possess the complete
FV genome (3), the partial expression ofwhich could result in the production of a
transplantation antigen .
Viral Antigen Expression : Cell Surface Antigen (FMR) .
￿
Mice immunized
against infectious FV produce two populations of antibodies in their sera : (a)
virus-neutralizing antibodies specific for VEA on the surfaces of both produc-
tively infected cells and intact progeny virus particles, and (b) cytotoxic antibod-
ies to the cell surface antigen (CSA) present on virus-infected cells, but not
present in antibody-accessible form on the surface of intact virus particles (12) .
These two antibody activities are properties of two separable populations of
antibodies that recognize different virus-coded polypeptides (13, 14) . The CSA
specificity induced by FV cross-reacts with CSA specificities similarly induced
by Moloney and Rauscher viruses, and has therefore been termed FMR (15) .
After regression of HFL/d-tc-produced solid tumors in BALB/c mice, hyperim-
munization with HFL/d-tc cells did not induce the production of antibodies
detectable in the complement-dependent cytotoxic assay, using guinea pig se-
rum as a complement source . Fig . 1 illustrates that sera from such animals
failed to show cytotoxic activity toward either the homologous immunogen,
cultured HFL/d-tc cells, or spleen cells from FV-infected BALB/c mice . When
HFL/d-tc cells taken at the 13th and 15th passages in vitro were tested directly
for sensitivity to complement-mediated cytolysis by a known anti-FMR serum,
these cells were completely resistant . Moreover, mechanically dispersed cells
from aprimary solid tumor derived by the subcutaneous implantation ofHFL/d-
tc cells harvested at the 13th passage in vitro were also resistant to cytotoxic
lysis by anti-FMR serum . In contrast, primary FV-infected syngeneic spleen
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Absence ofcytotoxic activity in hyperimmuneBALB/c anti-HFL/d-tc serum tested
on HFL/d-tc cells and on BALB/c FV-infected spleen cells . Control serum, A anti-Meth A
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cells exhibited characteristic immune cytolysis by anti-FMR serum. Both in-
fected spleen cells and HFL/d-tc cells were lysed by anti-H-2K.31 serum.
The absence of the FMR antigenic specificity on the surface of nonproducer
HFL/d-tc cells was confirmed by comparison of the quantitative absorption of
anti-FMR serum by normal syngeneic spleen cells, primary FV-infected synge-
neic spleen cells, and HFL/d-tc cells. Fig. 2 shows that the amount ofanti-FMR
absorbed by asfew as 2 x 105infected spleen cells was appreciable and increased
with increasing cell number. However, absorption with as many as 6 x 107
nonproducer HFL/d-tc cells did not decrease the cytotoxic activity of the anti-
FMR serum. This was true for normal syngeneic spleen cells, as well.
HFL/d-tc cellspassaged intraperitoneally in FV-infected syngeneic hostswere
harvested, washed three times in PBS, and assayed for sensitivity to comple-
ment-mediated cytolysis by anti-FMR and anti-H-2K.31 sera. Fig. 3 shows that
these ascitic HFL/d cells were completely resistantto lysis by anti-FMR serum,
whereas cytolysis by anti-H-2K.31 serum was readily demonstrable. Thus
HFL/d cells were resistant to immune cytolysis by anti-FMR serum even when
resident in viremic hosts. Cells from the enlarged spleens of these viremic,
autochthonous hosts lysed readily with both anti-FMR and anti-H-2K.31 sera,
as did spleen cells from syngeneic, FV-infected hosts.
Unlike HFL/d-tc cells, FV-producer HFL/b-sc and HFL/b-tc cells of BALB.B
origin did exhibit the cell surface antigenic specificity, FMR. In the present
study, this antigen was demonstrated by comparingthequantitative absorption
of cytotoxic anti-FMR serum with viable HFL/b-sc, HFL/b-tc, and HFL/d-tc
cells. Parallel absorption with normal and primary FV-infected BALB/c spleen
cells served as controls. It is apparent from thedata illustratedin Fig. 4 thatFV-
producer HFL/b-sc, HFL/b-tc, and primary infected spleen cells all absorbed
appreciable amounts of anti-FMR activity when as few as 3 x 10, cells were
used. Again, nonproducer HFL/d-tc cells did not absorb anti-FMR activity, even
at much higher cell concentrations.
From these studies we conclude that expression of FMR antigen correlates
with the virus-producer status of the HFL/b and HFL/d cell lines. HFL/d cells
express no FMR antigen, and therefore the transplantation antigen demon-
strated on these cells is not FMR. It is possible, however, that the higher level of
FIG. 2.
￿
Quantitative absorption of the cytotoxic (anti-FMR) activity of BALB/c anti-FV
antiserum by: (a) normal BALB/c spleen cells, (b) cultured nonproducer BALM tumor cells
(HFL/d-tc), and (c) primary FV-infected BALB/c spleen cells .1370 SURFACE ANTIGENS OF FRIEND VIRUS-INDUCED TUMOR CELLS
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Cytotoxic assay of BALB/c anti-FV (anti-FMR) and of A anti-Meth A (anti-H-
2K .31) antisera on HFL/d-tc cellsgrown in ascitic form in a FV-infected BALB/c mouse, on
spleen cells from the autochthonous host, and on FV-infected spleen cells from a control
BALB/c mouse .
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Quantitative assay for the capacity to absorb the cytotoxic activity ofBALB/c anti-
FV serum by : (a)normal BALB/c spleen cells, (b) cultured nonproducer BALB/c tumor cells
(HFL/d-tc), (c) primary FV-infected BALB/c spleen cells, (d) subcutaneously grownBALB .B
tumor cells (HFL/b-sc), and (e) cultured producer BALB.B tumor cells (HFL/b-tc) .
immunogenicity of HFL/b cells by comparison with HFL/d cells is due to the
presence of the FMR antigen .
Viral AntigenExpression : Virus EnvelopeAntigen (VEA) .
￿
After regression
of HFL/d-tc-produced solid tumors, BALB/c mice challenged with a high dose of
FV failed to develop splenomegaly . Normal control mice inoculated in parallel
with the same preparation of FV showed rapid and marked splenomegaly .
Furthermore, although sera from BALB/c mice hyperimmunized with HFL/d-tc
cells did not show cytotoxic activity, these sera did neutralize the spleen focus-
forming activity of FV and the helper activity of LLV-F . The kinetics of FV-
neutralization by this hyperimmune serum (BALB/c anti-HFL/d-tc) are shown
in Fig . 5, indicating aK value of 1.45±0.19. This demonstration of high titer
virus-neutralizing antibody suggests that FV-nonproducer, FMR-negative
HFL/d-tc cells express Friend VEA on their surfaces .
Additional evidence for the presence ofVEA on the surfaces of HFL/d-tc cells
was obtained by absorption studies . Hyperimmune serum raised against FV wasHERBERT A . FREEDMAN, FRANK LILLY, AND RICHARD A . STEEVES 1371
absorbed in parallel with equal numbers of viable HFL/d-tc cells, normal
syngeneic spleen cells, and primary FV-infected spleen cells . The neutralization
of FV by these absorbed sera is shown in Fig . 6. The results demonstrate that
nonproducer HFL/d-tc cells absorb virus-neutralizing antibody as effectively as
primary infected syngeneic spleen cells .
HFL/b-tc cells also bear VEA specificities, as expected from the fact that they
produce complete, infectious FV . BALB.B mice immunized with HFL/b-tc cells
show marked virus-neutralizing activity in their sera in addition to significant
levels of cytotoxic anti-FMR activity . Furthermore, HFL/b-tc cells, but not
normal BALB.B spleen cells, efficiently absorb virus-neutralizing activity from
anti-FV antiserum .
Loss of VEA .
￿
Around the 125th serial passage in culture, HFL/d-tc cells
began to show a much reduced capacity for inducing transplantation immunity
in vivo . The incidence of rejection of HFL/d-tc cells in syngeneic hosts was
markedly reduced. No more than 20% of all BALB/c animals receiving HFL/d-tc
cells intraperitoneally showed tumorregression, andthe incidence of regression
was near zero when HFL/d-tc cellswere inoculated subcutaneously . Thus, ithad
become extremely difficult to immunize BALB/c mice with these cells . Even in
those few BALB/c animals in whichhyperimmunization with HFL/d-tc cellswas
successful, neithercytotoxic nor virus-neutralizing antibodies could be detected.
Furthermore, HFL/d-tc cells could no longer boost the titerof virus-neutralizing
antibody in BALB/c mice previously hyperimmunized against VEA or absorb
the virus-neutralizing activity of hyperimmune anti-VEA serum. It therefore
appears that these HFL/d-tc cells no longer expressedVEA on their surfaces .
Previous studies, conductedduring the period of time in which HFL/d-tc cells
were VEA-positive, indicated that, although no infectious virus was produced,
these cells contained the genomes of both SFFV and its helper virus (3) . The
subsequent loss of VEA expression by HFL/d-tc cells, reported above, did not,
however, reflect loss ofone or both of these viral genomes . This was evidenced
by the recovery of infectious NB-tropic FV, i.e ., SFFV plus its original helper
virus, from VEA-negative HFL/d-tc cells in the absence of exogenously added
helper virus . Recovery of FV was accomplished either by intraperitoneal pas-
sage in syngeneic hosts (3) or by treatment in culture with 200 p.g/ml 5-iodo-2'-
deoxyuridine for 24 h. Since the tropism of the FV complex is determined by its
FIG . 5 .
￿
Kinetics of neutralization ofFV by hyperimmune BALB/c anti-HFL/d-tc serum,
tested at 1 :20 dilution .1372
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Neutralization ofFV by BALB/c anti-FV (1:20 dilution) absorbed with : (a) cul-
tured nonproducer BALB/c tumor cells (HFL/d-tc), (b) primary FV-infected BALB/c spleen
cells, and (c) normal BALB/c spleen cells .
helper virus component and since NB-tropic viruses are not known to occur
naturally, the recovery of NB-tropic FV would indicate the presence within
these nonproducer HFL/d-tc cells ofthe original helper virus genome . Therefore,
the loss of VEA expression by these cells reflects a further repression of these
viral genomes rather than their loss .
Although HFL/d-tc cells had become both FMR- and VEA-negative, it was
nonetheless possible, though considerably more difficult than before, to induce
transplantation immunity against them in syngeneic BALB/c mice . Moreover,
both BALB/c and BALB .B mice immunized with VEA-negative HFL/d-tc cells
were resistant to the disease syndrome resulting from FV inoculation. These
observations suggest the presence ofa virus-induced surface antigen other than
VEA orFMR on these cells .
Discussion
Both HFL/b and HFL/d cultured, FV-induced tumor cells have demonstrated
their capacity to induce transplantation immunity in theirrespective syngeneic
hosts . Thus both cell lines possess new, tumor-associated transplantation anti-
gens . This induction of transplantation immunitywas accomplished much more
readily in the HFL/b-BALB .B system than in the HFL/d-BALB/c system . It will
be important to determine if this difference is dueto (a) greater immunogenicity
of the HFL/b tumor cells, (b) greater immune responsiveness of BALB.B mice,
or (c) both .
We have observed a correlation betwen the expression of FV-associated anti-
gens and the induction of transplantation immunity. HFL/b-tc cells produce
complete, infectious FV which is released into the culture medium, and their
cell surfaces bear both VEA andFMR antigenic specificities . Either or both of
these specificities might act as transplantation antigens . HFL/d-tc cells, on the
other hand, make no detectable level of infectious FV and do not express the
FMR antigen . Thus, the absence ofan important viral antigen correlates with
the lower capacity of HFL/d-tc cells to induce transplantation immunity . Fur-
thermore, HFL/d-tc cells, which expressed Friend VEA for more than a 100
passages in culture, ceased to express this antigen at a point in time thatHERBERT A . FREEDMAN, FRANK LILLY, AND RICHARD A . STEEVES 1373
coincided with the observation of a marked further decrease in the capacity of
the cells to induce transplantation immunity in syngeneic hosts . These facts
make a circumstantial case for the interpretation that HFL/b cells are more
immunogenic than HFL/d cells because they express more viral antigens .
There is no evidence from the present experiments directly implicating the
relative immune responsiveness of BALB/c vs . BALB.B mice to FV-associated
tumor antigens . However, in unpublished studies in our laboratory, killer cells
specific for FV-infected target cells have been detected among the peritoneal
exudate population from BALB.B mice immunized with HFL/b-tc cells. Such
killer cells have not been detected to date in BALB/c mice immunized with
HFL/d-tc cells. This finding might reflect a difference betwen BALB.B and
BALB/c mice in specific immune responsiveness to a particular cell surface
antigen.
Previous studies in our laboratory (16) have shown that the amount of FMR
antigen activity detectable on the surface of spleen cells from FV-infected mice
decreases markedly in the late stages ofthe disease syndrome in BALB/cbut not
BALB.B mice . The present studies indicate that this phenomenon is also re-
flected in the persistent presence or absence of FMR antigen expression in
cultured tumor cell lines derived from these same mouse strains . Since the
presence or absence ofFMR antigen correlates with the FV-producer or nonpro-
ducer status of these cell lines, it is possible to pose the question : does the
suppressionof viral cell surface antigens inH-2d mice, bywhatever means, have
a causal relation to the observed nonproducerstatus ofthe HFL/d-tc tumor cells?
Our studies, so far, offer no answer to this question .
In addition to HFL/d-tc and HFL/b-tc, two other FV-induced tumor cell lines,
one of BALB/c and one of BALB .B origin, have been examined . Although the
BALB/c line, like HFL/d-tc, has become FV-nonproducer in culture and the
BALB.B line, like HFL/b-tc, has retained its FV-producer phenotype for over a
year in culture, it is not yet possible to infer on statistical grounds that the
difference inH2 genotype is responsible for these phenotypic differences. How-
ever, since these findings with tumor cell lines grown in vitro are consistent
with our earlier findings in vivo (16), the hypothesis that theH2 difference is a
major causal factor seems reasonable . These earlier studies in vivo further
indicated that antigen H-2K.31, like FMR, also showed a markedly decreased
expression on FV-infected BALB/c spleen cells in the late stages of the disease
syndrome . This findingmay suggest some molecular interaction betweentheH-
2 molecule and virus-associated molecules similar to the interaction suggested
by recent studies with lymphocytic choriomeningitis virus (17) .
Nonproducer HFL/d-tc cells do not express FMR, but the presence of Friend
VEA on the surface ofthese cells was demonstrated by : (a) the presence ofvirus-
neutralizing activity in the sera of mice immunized with syngeneic HFL/d-tc ;
and (b) the absorption of virus-neutralizing activity from hyperimmuneanti-FV
serum by HFL/d-tc cells . This was further confirmed by the finding of relatively
high levels of theMuLV envelope glycoprotein, gp69/71, in nonproducer HFL/d-
tc cell preparations (M . Strand and J. T. August, personal communication) .
FV represents a complex consisting of a replication-defective, erythroleuke-
mia-inducing virus, SFFV, together with its helper virus. Since it has been1374
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shown that the major VEA (gp69/71) of both SFFV and helper virus particles is
governed by the helper virus genome (18), the presence of Friend VEA on the
surface ofHFL/d-tc cells suggests that thesenonproducer cells possess all or part
ofthe helper virusgenome . Thus, in thepresentstudy, antibodies raised against
VEA-positive nonproducer HFL/d-tc cells neutralized both FV complex and
helper virus (LLV-F) isolated from the FV complex .
Moreover, the presence ofVEA onthe surfaces of nonproducer HFL/d-tc cells
provides a useful tool . Previously, it has been difficult to raise an antiserum
exhibiting virus-neutralizing (anti-VEA) activity without cytotoxic (anti-FMR)
activity as well . However, hyperimmunization ofBALB/c mice with syngeneic
VEA-positive nonproducer HFL/d-tc cells results in the production of virus-
neutralizing antiserum devoid of cytotoxic activity . Furthermore, it is possible,
using VEA-positive, FMR-negative HFL/d-tc cells, to absorb outvirus-neutraliz-
ing activity leaving intact the cytotoxic activity ofhyperimmune serum raised
against theFV complex.
Around the 125th serial passage in culture the HFL/d-tc cell line appeared to
have undergone a marked alteration in its antigenic characteristics . This
change was evidenced by the observations that : (a) the incidence of tumor
regression of HFL/d-tc cells in syngeneic hosts was markedly reduced, and thus
immunization of syngeneic mice with HFL/d-tc cells became difficult ; (b) even
when hyperimmunization of BALB/c mice with syngeneic HFL/d-tc cells was
successful, no virus-neutralizing activity could be detected in the serum of
immune mice ; and (c) HFL/d-tc cells could no longer either boost the titer of
virus-neutralizing antibody in BALB/c mice previously hyperimmunized
against VEA or absorb the virus neutralizing activity of hyperimmune anti-
VEA serum . In addition, HFL/d-tc cells, tested afterthe 160th serial passage in
culture, were negative for the viral envelope glycoprotein, gp69/71 (M . Strand
and J. T. August, personal communication) .
Thus the HFL/d-tc cell line has gone through three distinct phases in its 2-yr
passage history. During its very early passages, it produced small but demon-
strable amounts of complete FV (3) ; after about 14 passages in culture, it ceased
making any detectable level of infectious virus, and was found to be phenotypi-
cally FMR-negative, VEA-positive, and gp69/71-positive . More than 1 yr later
(125 serial passages in culture) it changed again, becoming VEA-negative and
gp69/71-negative .
Summary
BALB/cH2° (BALB.B) mice are less susceptible to the Friend virus (FV)
disease syndrome than congenic BALB/c (H2d) mice, and spleen cells from FV-
infected BALB.B mice are markedly less tumorigenic on transplantation to
syngeneic hoststhan those from FV-infected BALB/cmice . For these reasons we
investigated the expression o£ FV-associated cell surface antigens on cultured,
FV-transformed cell lines of BALB.B and BALB/c origin .
Both cell lines induced transplantation immunity in syngeneic hosts toward
furtherimplantations of the same tumor, BALB.B cellsbeingsignificantlymore
potent in this respect than BALB/c cells . BALB.B tumor cells, which produce
complete, infectious FV, expressed both the cell surface antigen, FMR (corre-HERBERT A . FREEDMAN, FRANK LILLY, AND RICHARD A . STEEVES 1375
sponding to the cytotoxic antibodies in anti-FV antisera), and virus envelope
antigen (VEA, corresponding to the virus-neutralizing antibodies in the anti-FV
antisera) . BALB/c tumor cells, on the other hand, which are FV-nonproducers,
expressed no FMR antigen, but did express VEA on their surfaces for at least
100 passages in culture . These cells could induce FV-neutralizing but not
cytotoxic anti-FMR antibodies when used to immunize syngeneic hosts . The
absence ofFMR antigen may be the basis for the reduced capacity of BALB/c
tumor cells, by comparisonwith BALB.B tumor cells, to induce transplantation
immunity .
After about the 125th serial transfer in culture, BALB/c tumor cells sponta-
neously ceased to express VEA and simultaneously became very weak inducers
of transplantation immunity in BALB/c hosts . This loss of VEA did not stem
from the loss of either the spleen focus-forming virus or the helper virus
genomes from these cells, since both viruses could still be recoveredfrom the cell
line .
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